Cryo-Cell International, Inc. - 10-K Summary (Fiscal Year Ended Nov 30, 2007)
Business Context and Reporting Period
Cryo-Cell International, Inc. is a smaller reporting company incorporated in Delaware, specializing in cellular processing and cryogenic storage. Its primary business is the collection and preservation of umbilical cord blood stem cells (U-Cord) for family use. The company operates a cGMP/cGTP-compliant facility in Oldsmar, Florida, and maintains international licensing agreements in Mexico, Central America, Ecuador, and India. The reporting period covers the fiscal year ended November 30, 2007.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 |
|---|---|---|
| Revenue | $17,460,196 | $17,180,383 |
| Net Loss | $(5,005,415) | $(2,811,368) |
| Loss Per Share (Basic/Diluted) | $(0.43) | $(0.24) |
| Cost of Sales | $6,592,145 (38% of Revenue) | $6,067,671 (35% of Revenue) |
| Operating Cash Flow | $(3,404,396) | $924,901 |
| Cash and Cash Equivalents (End of Period) | $3,364,711 | $7,414,140 |
| Debt | None (No indebtedness as of Feb 8, 2008) | None |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 2% to $17.46 million, driven by a price increase implemented in 2006 for new clients and an expanding customer base.
- Widening Loss: Net loss increased by approximately 78% (from $2.81M to $5.01M). This was primarily due to a 12% increase in marketing, general, and administrative expenses (MG&A) and a 9% increase in cost of sales.
- Expense Drivers: MG&A expenses rose by $1.5 million due to strategic marketing initiatives and approximately $874,000 in professional fees related to a proxy contest initiated by a dissident shareholder group. Stock option compensation expense increased to $266,000 following the adoption of SFAS 123(R).
- Cash Position: Cash and cash equivalents decreased by approximately $4.05 million, reflecting negative operating cash flow and capital expenditures for property and equipment.
Guidance, Outlook, and Risks
New Product Launch: In November 2007, the company launched "C'elle," a service for storing menstrual stem cells. This was a "soft launch" with preliminary sales pending full marketing and scientific publication. Conversely, the commercial launch of fetal placental stem cell services (Plureon) was postponed indefinitely in April 2007 due to technological commercialization considerations.
Liquidity Outlook: Management anticipates that existing cash, marketable securities, and operating cash flows will be sufficient to fund operations for at least the next 12 months. However, if revenue growth does not materialize or expenses exceed expectations, the company may need to reduce expenditures or seek equity/debt financing.
Key Risks and Contingencies:
- Legal Proceedings: The company is involved in ongoing patent litigation with PharmaStem Therapeutics, Inc. While a Federal Circuit Court ruled in Cryo-Cell's favor regarding infringement in July 2007, PharmaStem has requested Supreme Court review on patent validity. Additionally, a shareholder dispute resulted in a court order for a special shareholder meeting in March 2008.
- Revenue Sharing Agreements (RSAs): The company has long-term liabilities related to RSAs where it shares future storage revenue with investors. Payments totaling $1.07 million were made in 2007 and recorded as interest expense.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a material weakness surrounding accrued expenses.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $3.36 million cash balance given the $3.4 million negative operating cash flow and the $5 million net loss.
- Legal Exposure: Monitor the status of the PharmaStem patent litigation and the outcome of the March 2008 special shareholder meeting regarding the proxy contest.
- Revenue Quality: Assess the impact of the renegotiated international license agreements (Mexico and India) which capped royalties and reduced storage revenue percentages.
- Internal Controls: Review the remediation plan for the material weakness in accrued expenses identified in Item 9A.
- New Product Viability: Evaluate the commercial traction of the C'elle service, noting it is currently in a preliminary sales phase without full scientific validation published.